Tetraphase Pharmaceuticals (TTPH) Cut to Strong Sell at ValuEngine

ValuEngine cut shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a sell rating to a strong sell rating in a research report released on Friday.

TTPH has been the subject of several other reports. Needham & Company LLC reaffirmed a hold rating on shares of Tetraphase Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a hold rating to a buy rating and set a $7.75 price objective for the company in a research note on Saturday, September 23rd. BidaskClub downgraded Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, August 10th. Stifel Nicolaus reaffirmed a buy rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, September 12th. Finally, BMO Capital Markets raised their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an outperform rating in a research note on Wednesday, October 4th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $15.15.

Tetraphase Pharmaceuticals (TTPH) opened at $6.40 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.57 and a one year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis. sell-side analysts expect that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at $52,762.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System increased its position in Tetraphase Pharmaceuticals by 2.0% during the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock worth $1,727,000 after buying an additional 4,800 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Tetraphase Pharmaceuticals by 6.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 7,866 shares in the last quarter. Vanguard Group Inc. increased its position in Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares in the last quarter. Geode Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 17.0% during the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after buying an additional 45,554 shares in the last quarter. Finally, EcoR1 Capital LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $4,516,000. 58.19% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals (TTPH) Cut to Strong Sell at ValuEngine” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/04/tetraphase-pharmaceuticals-ttph-cut-to-strong-sell-at-valuengine.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What are top analysts saying about Tetraphase Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tetraphase Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit